Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
Holding INAB?
Track your performance easily
INAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $2.48
Previous Close$0.29
Volume7.29M
Average Volume (3M)930.40K
Market Cap
$13.40M
Enterprise Value$9.10M
Total Cash (Recent Filing)$10.20M
Total Debt (Recent Filing)$5.90M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding46,786,948
10 Day Avg. Volume3,941,893
30 Day Avg. Volume930,403
Standard Deviation0.29
R-Squared0.00013
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
IN8bio News
PremiumCompany Announcements
IN8bio Revises Executive Compensation and Severance Terms
Bulls Say, Bears Say
Bulls Say
Clinical Trials SuccessIn leukemia trial, 100% of patients (10/10) achieved durable complete remission (CR) at 1-year post stem cell transplant, beating standard of care RFS of 50-80%.
Regulatory ProgressIN8bio expects to have a Type B meeting with the FDA to discuss plans for a potential registrational trial.
Treatment AdvancementsHLA matching dramatically increased mPFS in r/r NHL patients—haplomatching increased mPFS by ~5X.
Bears Say
Clinical DataThe absence of a control arm and reliance on historical data comparisons may not benefit the stock with extended follow-up periods.
Financial PerformanceCapital overhang remains the key concern as In8bio had $10.2 million in cash and equivalents, with over $6 million per quarter in cash burn.
Stock SentimentA headwind from data shadow beyond 4Q24 exists, requiring strong belief in the stock for continued investor confidence.
---
Ownership Overview
47.34% Insiders
3.93% Mutual Funds
0.38% Other Institutional Investors
45.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $0.22 and its highest was $2.48 in the past 12 months.
What is IN8bio’s market cap?
Currently, no data Available
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Mar 13, 2025 which is in 128 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 08, 2024. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.173 by -$0.017.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Overvalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IN8bio have?
IN8bio has 46,786,950 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.173. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of IN8bio?
Among the largest hedge funds holding IN8bio’s share is Wela Strategies, Inc.. It holds IN8bio’s shares valued at N/A.
---
IN8bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.81%
12-Months-Change
Fundamentals
Return on Equity
-180.45%
Trailing 12-Months
Asset Growth
-24.30%
Trailing 12-Months
Company Description
IN8bio
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
---
INAB Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering INAB
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-59.21%
reiterated a buy rating 5 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.21% per trade.
---